The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.
 
Siwen Hu-Lieskovan
Consulting or Advisory Role - Amgen; Emergent BioSolutions; Merck; Novartis; Vaccinex
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst)
 
Zeynep Eroglu
No Relationships to Disclose
 
Jesse Meir Zaretsky
No Relationships to Disclose
 
Dae Won Kim
No Relationships to Disclose
 
Alain Patrick Algazi
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Oncosec (Inst)
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Genoptix
Research Funding - Incyte
 
Elizabeth Liniker
No Relationships to Disclose
 
Ben Kong
No Relationships to Disclose
 
Rodrigo Munhoz
No Relationships to Disclose
 
Suthee Rapisuwon
Research Funding - Bristol-Myers Squibb
 
Bartosz Chmielowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Immunocore; Merck
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Janssen; Merck
 
Jeffrey Alan Sosman
No Relationships to Disclose
 
Richard A. Scolyer
No Relationships to Disclose
 
Richard Wayne Joseph
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Genoptix; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech (Inst); X4 Pharma (Inst)
 
Michael Andrew Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Wen-Jen Hwu
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck/Schering Plough
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis